Stoke Therapeutics’ (STOK) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a $35.00 target price on the stock.

A number of other research firms have also issued reports on STOK. Chardan Capital began coverage on Stoke Therapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $24.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Leerink Partners started coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 price target for the company. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $9.00 on Wednesday. The company has a market cap of $476.70 million, a P/E ratio of -4.29 and a beta of 0.95. Stoke Therapeutics has a 1-year low of $4.09 and a 1-year high of $17.58. The stock has a 50-day moving average of $11.91 and a two-hundred day moving average of $13.04.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The firm had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, analysts anticipate that Stoke Therapeutics will post -2.03 EPS for the current fiscal year.

Insider Activity at Stoke Therapeutics

In other news, insider Barry Ticho sold 13,945 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $178,217.10. Following the completion of the sale, the insider now directly owns 47,332 shares of the company’s stock, valued at approximately $604,902.96. This represents a 22.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Jonathan Allan sold 9,696 shares of Stoke Therapeutics stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the completion of the transaction, the general counsel now directly owns 35,142 shares in the company, valued at $449,114.76. The trade was a 21.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 62,849 shares of company stock valued at $809,421 over the last ninety days. Insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in STOK. Barclays PLC lifted its position in Stoke Therapeutics by 145.3% during the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after acquiring an additional 47,239 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Stoke Therapeutics by 9.7% during the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock worth $10,705,000 after purchasing an additional 76,661 shares during the period. State Street Corp grew its position in Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after buying an additional 137,145 shares during the last quarter. RTW Investments LP increased its stake in Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after buying an additional 427,447 shares during the period. Finally, BNP Paribas Financial Markets raised its position in Stoke Therapeutics by 1,589.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock worth $936,000 after buying an additional 71,647 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.